Goldman Sachs
MBOT icon

Goldman Sachs’s Microbot Medical MBOT Stock Holding History

Goldman Sachs’s Portfolio MBOT Stock Details MBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-309,103
Closed -$745K – 6828
2026
Q1 		$745K Buy
309,103
+274,640
+797% +$613K ﹤0.01% 5309
2025
Q4 		$68.9K Buy
+34,463
New +$81.6K ﹤0.01% 6252
2025
Q3 		– Sell
-34,003
Closed -$85.7K – 6534
2025
Q2 		$85.7K Sell
34,003
-3,741
-10% -$8.95K ﹤0.01% 5845
2025
Q1 		$57K Buy
+37,744
New +$66.7K ﹤0.01% 5868
2017
Q2 		– Sell
-1,104
Closed -$96K – 6872
2017
Q1 		$96K Buy
+1,104
New +$96.9K ﹤0.01% 6078
2016
Q3 		– Sell
-113
Closed -$6K – 7115
2016
Q2 		$6K Buy
+113
New +$32.6K ﹤0.01% 6918
2014
Q4 		– Sell
-49
Closed -$101K – 7226
2014
Q3 		$101K Buy
49
+40
+444% +$106K ﹤0.01% 6576
2014
Q2 		$28K Buy
+9
New +$20.8K ﹤0.01% 6839

Other funds holding MBOT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Goldman Sachs's MBOT Position: Q2 2026 in Review

Goldman Sachs sold out of Microbot Medical (MBOT) in Q2 2026, closing a stake of 309,103 shares — an estimated $745K sold.

Goldman Sachs first reported a position in MBOT in Q2 2014 and held it in 8 quarters. The position peaked at $745K in Q1 2026. 71 funds tracked by Wall St. Rank hold MBOT as of Q2 2026.

  • Goldman Sachs reported no remaining Microbot Medical position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 309,103 Microbot Medical shares in Q2 2026, an estimated $745K.
  • Goldman Sachs first reported a position in Microbot Medical in Q2 2014 and held it in 8 quarters.
  • Goldman Sachs's Microbot Medical position peaked at $745K in Q1 2026.
  • 71 funds tracked by Wall St. Rank held Microbot Medical as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.